The role of stroma in pancreatic cancer: Diagnostic and therapeutic implications

Nature Reviews Gastroenterology and Hepatology

Volumn 9, Issue 8, 2012, Pages 454-467

  Erkan, Mert ^a   Hausmann, Simone ^a   Michalski, Christoph W ^a   Fingerle, Alexander A ^a   Dobritz, Martin ^a   Kleeff, Jãrg ^a   Friess, Helmut ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; CANDESARTAN; ELLAGIC ACID; GEMCITABINE; LOSARTAN; PACLITAXEL; PERINDOPRIL; RECOMBINANT HYALURONIDASE;

ACINAR CELL; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CARCINOGENESIS; CHRONIC PANCREATITIS; COMPUTER ASSISTED TOMOGRAPHY; CYSTIC FIBROSIS; DIAGNOSTIC VALUE; DRUG TARGETING; ENDOSCOPIC ECHOGRAPHY; FIBROBLAST; HUMAN; MATHEMATICAL MODEL; MOLECULAR IMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS ADENOCARCINOMA; PANCREATIC STELLATE CELL; PRECANCER; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; STROMA; TISSUE PERFUSION; TISSUE REACTION; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

ADENOCARCINOMA; ANIMALS; CARCINOMA, PANCREATIC DUCTAL; HUMANS; IMMUNOHISTOCHEMISTRY; PANCREATIC NEOPLASMS; PANCREATIC STELLATE CELLS; RENIN-ANGIOTENSIN SYSTEM; STROMAL CELLS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84864832834     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2012.115     Document Type: Review

References (127)

1. Jemal, A. et al. Global cancer statistics. CA Cancer J. Clin. 61, 69-90 (2011).
2. Raimondi, S. et al. Epidemiology of pancreatic cancer: an overview. Nat. Rev. Gastroenterol. Hepatol. 6, 699-708 (2009).
3. Winter, J. M. et al. Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades. Ann. Surg. Oncol. 19, 169-175 (2012).
4. Conroy, T. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364, 1817-1825 (2011).
5. Conroy, T. et al. Metastatic pancreatic cancer: old drugs, new paradigms. Curr. Opin. Oncol. 23, 390-395 (2011).
6. Kessenbrock, K. et al. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141, 52-67 (2010).
7. Kindler, H. L. et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J. Clin. Oncol. 28, 3617-3622 (2010).
8. Overall, C. M. et al. Tumour microenvironment-opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat. Rev. Cancer 6, 227-239 (2006). (Pubitemid 43292566)
9. Paez-Ribes, M. et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15, 220-231 (2009).
10. Moore, M. J. et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25, 1960-1966 (2007). (Pubitemid 46972777)
11. Erkan, M. et al. The impact of the activated stroma on pancreatic ductal adenocarcinoma biology and therapy resistance. Curr. Mol. Med. 12, 288-303 (2012).
12. Erkan, M. et al. The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Clin. Gastroenterol. Hepatol. 6, 1155-1161 (2008).
13. Mollenhauer, J., Roether, I. & Kern, H. F. Distribution of extracellular matrix proteints in pancreatic ductal adenocarcinoma and its influence on tumor cell proliferation in vitro. Pancreas 2, 14-24 (1987).
14. Apte, M. V. et al. Periacinar stellate shaped cells in rat pancreas: identification, isolation, and culture. Gut 43, 128-133 (1998). (Pubitemid 28335501)
15. Apte, M. V. et al. Dangerous liaisons: pancreatic stellate cells and pancreatic cancer cells. J. Gastroenterol. Hepatol. 27 (Suppl. 2), 69-74 (2012).
16. Bachem, M. G. et al. Identification, culture, and characterization of pancreatic stellate cells in rats and humans. Gastroenterology 115, 421-432 (1998).
17. Bachem, M. G. et al. Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology 128, 907-921 (2005). (Pubitemid 40523543)
18. Erkan, M. et al. StellaTUM: current consensus and discussion on pancreatic stellate cell research. Gut 61, 172-178 (2012).
19. Erkan, M. et al. Periostin creates a tumor-supportive microenvironment in the pancreas by sustaining fibrogenic stellate cell activity. Gastroenterology 132, 1447-1464 (2007). (Pubitemid 46627568)
20. Erkan, M. et al. Cancer-stellate cell interactions perpetuate the hypoxia-fibrosis cycle in pancreatic ductal adenocarcinoma. Neoplasia 11, 497-508 (2009).
21. Hwang, R. F. et al. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res. 68, 918-926 (2008). (Pubitemid 351206771)
22. Paron, I. et al. Tenascin?C enhances pancreatic cancer cell growth and motility and affects cell adhesion through activation of the integrin pathway. PLoS ONE 6, e21684 (2011).
23. Vonlaufen, A. et al. Pancreatic stellate cells: partners in crime with pancreatic cancer cells. Cancer Res. 68, 2085-2093 (2008). (Pubitemid 351521780)
24. Omary, M. B., Lugea, A., Lowe, A. W. & Pandol, S. J. The pancreatic stellate cell: a star on the rise in pancreatic diseases. J. Clin. Invest. 117, 50-59 (2007). (Pubitemid 46048449)
25. Apte, M. V. & Wilson, J. S. Dangerous liaisons: pancreatic stellate cells and pancreatic cancer cells. J. Gastroenterol. Hepatol. 27 (Suppl. 2), 69-74 (2012).
26. Kelsen, D. P. et al. Pain and depression in patients with newly diagnosed pancreas cancer. J. Clin. Oncol. 13, 748-755 (1995).
27. Klein, A. P. et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res. 64, 2634-2638 (2004). (Pubitemid 38523922)
28. Giardiello, F. M. et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 119, 1447-1453 (2000). (Pubitemid 32198669)
29. Lowenfels, A. B. et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N. Engl. J. Med. 328, 1433-1437 (1993). (Pubitemid 23143844)
30. Canto, M. I. et al. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology 142, 796-804 (2012).
31. Holzapfel, K. et al. Comparison of diffusion-weighted MR imaging and multidetector-row CT in the detection of liver metastases in patients operated for pancreatic cancer. Abdom. Imaging 36, 179-184 (2011).
32. Aichler, M. et al. Origin of pancreatic ductal adenocarcinoma from atypical flat lesions: a comparative study in transgenic mice and human tissues. J. Pathol. 226, 723-734 (2011).
33. Brune, K. et al. Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am. J. Surg. Pathol. 30, 1067-1076 (2006). (Pubitemid 44299338)
34. Pérez-Mancera, P. A. et al. What we have learned about pancreatic cancer from mouse models. Gastroenterology 142, 1079-1092 (2012).
35. Hernandez-Munoz, I. et al. Pancreatic ductal adenocarcinoma: cellular origin, signaling pathways and stroma contribution. Pancreatology 8, 462-469 (2008).
36. Pour, P. Islet cells as a component of pancreatic ductal neoplasms. I. Experimental study: ductular cells, including islet cell precursors, as primary progenitor cells of tumors. Am. J. Pathol. 90, 295-316 (1978).
37. Kong, B. et al. AZGP1 is a tumor suppressor in pancreatic cancer inducing mesenchymal?to?epithelial transdifferentiation by inhibiting TGFmediated ERK signaling. Oncogene 29, 5146-5158 (2010).
38. Hruban, R. H. et al. Update on pancreatic intraepithelial neoplasia. Int. J. Clin. Exp. Pathol. 1, 306-316 (2008).
39. Matthaei, H. et al. Cystic precursors to invasive pancreatic cancer. Nat. Rev. Gastroenterol. Hepatol. 8, 141-150 (2011).
40. Salvia, R. et al. Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. Ann. Surg. 239, 678-685 (2004).
41. Sohn, T. A. et al. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann. Surg. 239, 788-797 (2004).
42. Yamao, K. et al. The prognosis of intraductal papillary mucinous tumors of the pancreas. Hepatogastroenterology 47, 1129-1134 (2000).
43. Maire, F. et al. Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with pancreatic ductal adenocarcinoma. Gut 51, 717-722 (2002). (Pubitemid 35216862)
44. Stanger, B. Z. et al. Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell 8, 185-195 (2005). (Pubitemid 41317590)
45. Wagner, M. et al. A murine tumor progression model for pancreatic cancer recapitulating the genetic alterations of the human disease. Genes Dev. 15, 286-293 (2001). (Pubitemid 32155144)
46. Erkan, M. et al. Tumor microenvironment and progression of pancreatic cancer. Exp. Oncol. 32, 128-131 (2010).
47. Eser, S. et al. In vivo diagnosis of murine pancreatic intraepithelial neoplasia and early-stage pancreatic cancer by molecular imaging. Proc. Natl Acad. Sci. USA 108, 9945-9950 (2011).
48. Guerra, C. et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K?Ras oncogenes in adult mice. Cancer Cell 11, 291-302 (2007). (Pubitemid 46349841)
49. Barcellos-Hoff, M. H. et al. Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res. 60, 1254-1260 (2000). (Pubitemid 30151992)
50. Radisky, E. S. et al. Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J. Mammary Gland Biol. Neoplasia 15, 201-212 (2010).
51. Sternlicht, M. D. et al. The stromal proteinase MMP3/stromelysin?1 promotes mammary carcinogenesis. Cell 98, 137-146 (1999). (Pubitemid 29344902)
52. Guturu, P. et al. Interplay of tumor microenvironment cell types with parenchymal cells in pancreatic cancer development and therapeutic implications. J. Gastrointest. Cancer 40, 1-9 (2009).
53. Masamune, A. et al. Fibrinogen induces cytokine and collagen production in pancreatic stellate cells. Gut 58, 550-559 (2009).
54. Pandol, S. et al. Desmoplasia of pancreatic ductal adenocarcinoma. Clin. Gastroenterol. Hepatol. 7 (11 Suppl.), S44-S47 (2009).
55. Radisky, D. C. et al. Matrix metalloproteinase-induced fibrosis and malignancy in breast and lung. Proc. Am. Thorac. Soc. 5, 316-322 (2008). (Pubitemid 351520677)
56. Erkan, M. et al. Organ?, inflammation- and cancer specific transcriptional fingerprints of pancreatic and hepatic stellate cells. Mol. Cancer 9, 88 (2010).
57. Pilarsky, C. et al. Activation of Wnt signalling in stroma from pancreatic cancer identified by gene expression profiling. J. Cell. Mol. Med. 12, 2823-2835 (2008).
58. Masamune, A. et al. Hypoxia stimulates pancreatic stellate cells to induce fibrosis and angiogenesis in pancreatic cancer. Am. J. Physiol. Gastrointest. Liver Physiol. 295, G709-G717 (2008).
59. Jacobetz, M. A. et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut http:// dx.doi.org/10.1136/ gutjnl-2012-302529.
60. Samkharadze, T. et al. Pigment epithelium-derived factor associates with neuropathy and fibrosis in pancreatic cancer. Am. J. Gastroenterol. 106, 968-980 (2011).
61. Herrmann, K. et al. Comparison of 3'?deoxy?3'?[(18)F]fluorothymidine positron emission tomography (FLT PET) and FDG PET/CT for the detection and characterization of pancreatic tumours. Eur. J. Nucl. Med. Mol. Imaging 39, 846-851 (2012).
62. Bausch, D. et al. Plectin?1 as a novel biomarker for pancreatic cancer. Clin. Cancer Res. 17, 302-309 (2011).
63. Cruz-Monserrate, Z. et al. Detection of pancreatic cancer tumours and precursor lesions by cathepsin E activity in mouse models. Gut http://dx.doi.org/10.1136/gutjnl-2011-300544.
64. de Visser, M. et al. Novel 111In-labelled bombesin analogues for molecular imaging of prostate tumours. Eur. J. Nucl. Med. Mol. Imaging 34, 1228-1238 (2007). (Pubitemid 47296771)
65. Delrue, L. J. et al. Assessment of neovascular permeability in a pancreatic tumor model using dynamic contrast-enhanced (DCE) MRI with contrast agents of different molecular weights. MAGMA 24, 225-232 (2011).
66. Djidja, M. C. et al. MALDI-ion mobility separation-mass spectrometry imaging of glucose-regulated protein 78 kDa (Grp78) in human formalin-fixed, paraffin-embedded pancreatic adenocarcinoma tissue sections. J. Proteome Res. 8, 4876-4884 (2009).
67. Hilderbrand, S. A. et al. Near infrared fluorescence-based bacteriophage particles for ratiometric pH imaging. Bioconjug. Chem. 19, 1635-1639 (2008).
68. Kelly, K. A. et al. Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma. PLoS Med. 5, e85 (2008).
69. Kim, Y. H. et al. An RNA aptamer that specifically binds pancreatic adenocarcinoma up-regulated factor inhibits migration and growth of pancreatic cancer cells. Cancer Lett. 313, 76-83 (2011).
70. Kimura, R. H. et al. Pharmacokinetically stabilized cystine knot peptides that bind alpha?v?beta?6 integrin with single-digit nanomolar affinities for detection of pancreatic cancer. Clin. Cancer Res. 18, 839-849 (2012).
71. Morse, D. L. et al. Identification of novel pancreatic adenocarcinoma cell-surface targets by gene expression profiling and tissue microarray. Biochem. Pharmacol. 80, 748-754 (2010).
72. Partecke, I. L. et al. In vivo imaging of pancreatic tumours and liver metastases using 7 Tesla MRI in a murine orthotopic pancreatic cancer model and a liver metastases model. BMC Cancer 11, 40 (2011).
73. Rialon, K. L. et al. Aptamers: potential applications to pancreatic cancer therapy. Anticancer Agents Med. Chem. 11, 434-441 (2011).
74. Yang, L. et al. Molecular imaging of pancreatic cancer in an animal model using targeted multifunctional nanoparticles. Gastroenterology 136, 1514-1525.e2 (2009).
75. Zaman, M. B. et al. Single-domain antibody bioconjugated near-IR quantum dots for targeted cellular imaging of pancreatic cancer. J. Nanosci. Nanotechnol. 11, 3757-3763 (2011).
76. Farace, P. et al. DCE-MRI using small-molecular and albumin-binding contrast agents in experimental carcinomas with different stromal content. Eur. J. Radiol. 78, 52-59 (2011).
77. Fukushima, N. et al. Periostin deposition in the stroma of invasive and intraductal neoplasms of the pancreas. Mod. Pathol. 21, 1044-1053 (2008).
78. Phillips, P. A. et al. Pancreatic stellate cells produce acetylcholine and may play a role in pancreatic exocrine secretion. Proc. Natl Acad. Sci. USA 107, 17397-17402 (2010).
79. Masamune, A. et al. NADPH oxidase plays a crucial role in the activation of pancreatic stellate cells. Am. J. Physiol. Gastrointest. Liver Physiol. 294, G99-G108 (2008).
80. Zhang, W. et al. Expression of extracellular matrix metalloproteinase inducer (EMMPRIN/CD147) in pancreatic neoplasm and pancreatic stellate cells. Cancer Biol. Ther. 6, 218-227 (2007). (Pubitemid 46641626)
81. Jiang, X. et al. Pancreatic islet and stellate cells are the main sources of endocrine gland-derived vascular endothelial growth factor/prokineticin?1 in pancreatic cancer. Pancreatology 9, 165-172 (2009).
82. Masamune, A. et al. Pancreatic stellate cells express Toll-like receptors. J. Gastroenterol. 43, 352-362 (2008). (Pubitemid 351958899)
83. Olive, K. P. et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457-1461 (2009).
84. Xu, Z. et al. Role of pancreatic stellate cells in pancreatic cancer metastasis. Am. J. Pathol. 177, 2585-2596 (2010).
85. Esposito, I. et al. Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma. J. Clin. Pathol. 57, 630-636 (2004). (Pubitemid 38725766)
86. Folkman, J. Angiogenesis. Annu. Rev. Med. 57, 1-18 (2006). (Pubitemid 43261975)
87. Reiser-Erkan, C. et al. Hypoxia-inducible proto-oncogene Pim?1 is a prognostic marker in pancreatic ductal adenocarcinoma. Cancer Biol. Ther. 7, 1352-1359 (2008).
88. Michalski, C. W. et al. Mononuclear cells modulate the activity of pancreatic stellate cells which in turn promote fibrosis and inflammation in chronic pancreatitis. J. Transl. Med. 5, 63 (2007).
89. Michalski, C. W. et al. Cannabinoids reduce markers of inflammation and fibrosis in pancreatic stellate cells. PLoS ONE 3, e1701 (2008).
90. Krizhanovsky, V. et al. Senescence of activated stellate cells limits liver fibrosis. Cell 134, 657-667 (2008).
91. Von Hoff, D. D. et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J. Clin. Oncol. 29, 4548-4554 (2011).
92. Oparil, S. et al. The renin-angiotensin system (second of two parts). N. Engl. J. Med. 291, 446-457 (1974).
93. Oparil, S. et al. The renin-angiotensin system (first of two parts). N. Engl. J. Med. 291, 389-401 (1974).
94. Peach, M. J. Renin-angiotensin system: biochemistry and mechanisms of action. Physiol. Rev. 57, 313-370 (1977). (Pubitemid 8097628)
95. Paul, M. et al. Physiology of local renin-angiotensin systems. Physiol. Rev. 86, 747-803 (2006). (Pubitemid 44033382)
96. Tsang, S. W. et al. The role of the pancreatic renin-angiotensin system in acinar digestive enzyme secretion and in acute pancreatitis. Regul. Pept. 119, 213-219 (2004). (Pubitemid 38553840)
97. Tsang, S. W. et al. Prophylactic and therapeutic treatments with AT 1 and AT 2 receptor antagonists and their effects on changes in the severity of pancreatitis. Int. J. Biochem. Cell Biol. 36, 330-339 (2004). (Pubitemid 37487767)
98. Kuno, A. et al. Angiotensin-converting enzyme inhibitor attenuates pancreatic inflammation and fibrosis in male Wistar Bonn/Kobori rats. Gastroenterology 124, 1010-1019 (2003). (Pubitemid 36389804)
99. Ulmasov, B. et al. Protective role of angiotensin II type 2 receptor signaling in a mouse model of pancreatic fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol. 296, G284-G294 (2009).
100. Sakurai, T. et al. Involvement of angiotensin II and reactive oxygen species in pancreatic fibrosis. Pancreatology 11 (Suppl. 2), 7-13 (2011).
101. Ulmasov, B. et al. Angiotensin II signaling through the AT1a and AT1b receptors does not have a role in the development of cerulein-induced chronic pancreatitis in the mouse. Am. J. Physiol. Gastrointest. Liver Physiol. 299, G70-G80 (2010).
102. Ernsberger, P. et al. Metabolic actions of angiotensin receptor antagonists: PPAR-gamma agonist actions or a class effect? Curr. Opin. Pharmacol. 7, 140-145 (2007). (Pubitemid 46404747)
103. Ling, M. T. et al. Tocotrienol as a potential anticancer agent. Carcinogenesis 33, 233-239 (2012).
104. Li, X. C. et al. alpha-Tocopherol treatment ameliorates chronic pancreatitis in an experimental rat model induced by trinitrobenzene sulfonic acid. Pancreatology 11, 5-11 (2011).
105. Rickmann, M. et al. Tocotrienols induce apoptosis and autophagy in rat pancreatic stellate cells through the mitochondrial death pathway. Gastroenterology 132, 2518-2532 (2007). (Pubitemid 46890868)
106. Jiang, F. et al. Comparison of antioxidative and antifibrotic effects of alpha-tocopherol with those of tocotrienol-rich fraction in a rat model of chronic pancreatitis. Pancreas 40, 1091-1096 (2011).
107. Priyadarsini, K. I. et al. Free radical studies of ellagic acid, a natural phenolic antioxidant. J. Agric. Food Chem. 50, 2200-2206 (2002). (Pubitemid 34260032)
108. Iino, T. et al. Effect of ellagic acid on gastric damage induced in ischemic rat stomachs following ammonia or reperfusion. Life Sci. 70, 1139-1150 (2002). (Pubitemid 34137082)
109. Thresiamma, K. C. et al. Inhibition of liver fibrosis by ellagic acid. Indian J. Physiol. Pharmacol. 40, 363-366 (1996). (Pubitemid 26420820)
110. Masamune, A. et al. Ellagic acid blocks activation of pancreatic stellate cells. Biochem. Pharmacol. 70, 869-878 (2005). (Pubitemid 41138851)
111. Suzuki, N. et al. Ellagic acid inhibits pancreatic fibrosis in male Wistar Bonn/Kobori rats. Dig. Dis. Sci. 54, 802-810 (2009).
112. Ratnam, D. V. et al. Simultaneous analysis of ellagic acid and coenzyme Q(10) by derivative spectroscopy and HPLC. Talanta 70, 387-391 (2006). (Pubitemid 44223637)
113. Kitamura, M. et al. Epigallocatechin gallate suppresses peritoneal fibrosis in mice. Chem. Biol. Interact. 195, 95-104 (2012).
114. Kim, N. et al. Formation of vitamin A lipid droplets in pancreatic stellate cells requires albumin. Gut 58, 1382-1390 (2009).
115. Masamune, A. et al. Signal transduction in pancreatic stellate cells. J. Gastroenterol. 44, 249-260 (2009).
116. Kunz-Schughart, L. A. et al. A heterologous 3?D coculture model of breast tumor cells and fibroblasts to study tumor-associated fibroblast differentiation. Exp. Cell Res. 266, 74-86 (2001). (Pubitemid 32989044)
117. Mersmann, M. et al. Human antibody derivatives against the fibroblast activation protein for tumor stroma targeting of carcinomas. Int. J. Cancer 92, 240-248 (2001). (Pubitemid 32225376)
118. Cheng, J. D. et al. Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. Cancer Res. 62, 4767-4772 (2002).
119. Loeffler, M. et al. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J. Clin. Invest. 116, 1955-1962 (2006). (Pubitemid 44033319)
120. Kraman, M. et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 330, 827-830 (2010).
121. Morris, J. P. 4th, Wang, S. C. & Hebrok, M. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat. Rev. Cancer 10, 683-695 (2010).
122. Yauch, R. L. et al. A paracrine requirement for hedgehog signalling in cancer. Nature 455, 406-410 (2008).
123. Tian, H. et al. Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis. Proc. Natl Acad. Sci. USA 106, 4254-4259 (2009).
124. Beatty, G. L. et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331, 1612-1616 (2011).
125. Pinzani, M. Pancreatic stellate cells: new kids become mature. Gut 55, 12-14 (2006). (Pubitemid 41820628)
126. Langton, C. Studying artificial life with cellular automata. Physica D: Nonlinear Phenomena 22, 120-149 (1986).
127. Branda, C. S. et al. Talking about a revolution: The impact of site-specific recombinases on genetic analyses in mice. Dev. Cell 6, 7-28 (2004). (Pubitemid 38089202)